RNA oligomers at atomic resolution containing 1‐methylpseudouridine, an essential building block of mRNA vaccines-Reference-Cited by-同舟云学术

RNA oligomers at atomic resolution containing 1‐methylpseudouridine, an essential building block of mRNA vaccines

Published:2024-02-29 Issue:7 Volume:19 Page:
ISSN:1860-7179
Container-title:ChemMedChem
language:en
Short-container-title:ChemMedChem

Author:

Nievergelt Philipp¹^ORCID,Berliat Florian¹,McAuley Katherine E.²^ORCID,Dorgan Colin R.³,van Well Renate Maria³,Thorn Andrea⁴^ORCID,Spingler Bernhard¹^ORCID

Affiliation:

1. Department of Chemistry University of Zurich 8057 Zurich Switzerland

2. Paul Scherrer Institute 5232 Villigen PSI Switzerland

3. Biosynth Limited Compton Berkshire RG20 6NE United Kingdom

4. Institut für Nanostruktur und Festkörperphysik Universität Hamburg 22761 Hamburg Germany

Abstract

AbstractAll widely used mRNA vaccines against COVID‐19 contain in their sequence 1‐methylpseudouridine (m1Ψ) instead of uridine. In this publication, we report two high resolution crystal structures (at up to 1.01 and 1.32 Å, respectively) of one such double‐stranded 12‐mer RNA sequence crystallized in two crystal forms. The structures are compared with similar structures which do not contain this modification. Additionally, the X‐ray structure of 1‐methyl‐pseudouridine itself was determined.

Funder

Universität Zürich

Lawrence Berkeley National Laboratory

Pennsylvania State University

Universität Wien

Publisher

Wiley

Reference41 articles.

1. Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA

2. Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability

3. Press release of the Nobel Assembly The Nobel Prize in Physiology or Medicine 2023 https://www.nobelprize.org/prizes/medicine/2023/press-release/ date accessed: 2ndOct 2023.

4. BNT162b vaccines protect rhesus macaques from SARS-CoV-2

5. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness